{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:03:45Z","timestamp":1783573425101,"version":"3.55.0"},"reference-count":37,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100013327","name":"H. Lundbeck A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Euro J of Neurology"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      This post hoc analysis examined the reduction in monthly headache days (\n                      <jats:styled-content style=\"fixed-case\">MHDs<\/jats:styled-content>\n                      ) by frequency category shifts and associated improvements following eptinezumab treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The DELIVER trial evaluated eptinezumab in adults with migraine for whom 2\u20134 previous preventive treatments failed. During a 24\u2010week, double\u2010blind, placebo\u2010controlled period followed by a 48\u2010week extension period, participants received IV eptinezumab 100\u2009mg, 300\u2009mg, or placebo every 12\u2009weeks, with all receiving eptinezumab beginning Week 25 (dose\u2010blinded). Participants were categorized by MHD frequency: &gt;\u200914, 8\u201314, 4 to &lt;\u20098, 1 to &lt;\u20094, 0. MHD category shifts were evaluated in the total population and several subgroups (including participants with &gt;\u200914 baseline MHDs and early \u2265\u200950% responders). In participants reporting &lt;\u20098 MHDs after all doses, the associated changes in headache intensity and disease status were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of randomized participants, 88% (782\/890) completed the trial. The percentage of participants randomized initially to eptinezumab who reported &lt;\u20094 MHDs was 23% (138\/592) over Weeks 1\u201312 and 47% (236\/498) over Weeks 61\u201372; 9% reported 0 MHDs after the final dose. Of participants randomized initially to eptinezumab who shifted from \u2265\u20098 MHDs at baseline to &lt;\u20098 over Weeks 1\u201312, 71% (170\/241) reported &lt;\u20098 MHDs for the rest of the trial; of those who shifted from &gt;\u200914 to &lt;\u20098 MHDs, 66% (49\/74) reported &lt;\u20098 MHDs for the rest of the trial. Reduction to &lt;\u20098 MHDs was associated with robust improvements in headache intensity and disease burden.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Eptinezumab was associated with sustained reduction in MHD category, with some achieving headache\/migraine freedom in patients with a history of preventive treatments that failed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                      (identifier: NCT04418765;\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04418765\">https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04418765<\/jats:ext-link>\n                      ) and EudraCT (identifier: 2019\u2010004497\u201025;\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=2019-004497-25\">https:\/\/www.clinicaltrialsregister.eu\/ctr\u2010search\/search?query=2019\u2010004497\u201025<\/jats:ext-link>\n                      )\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ene.70460","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T13:51:54Z","timestamp":1765806714000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Early and Sustained Shift in Headache Day Frequency Following Eptinezumab Treatment in Adults With Migraine for Whom 2\u20134 Previous Preventive Treatments Have Failed: A Post Hoc Analysis of the Randomized\n                    <scp>DELIVER<\/scp>\n                    Trial"],"prefix":"10.1111","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1513-2113","authenticated-orcid":false,"given":"Cristina","family":"Tassorelli","sequence":"first","affiliation":[{"name":"Department of Brain and Behavioural Sciences University of Pavia  Pavia Italy"},{"name":"IRCCS C. Mondino Foundation  Pavia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1334-1157","authenticated-orcid":false,"given":"Amaal J.","family":"Starling","sequence":"additional","affiliation":[{"name":"Mayo Clinic Arizona  Scottsdale Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5060-7404","authenticated-orcid":false,"given":"Susanne F.","family":"Awad","sequence":"additional","affiliation":[{"name":"H. Lundbeck A\/S  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1102-3756","authenticated-orcid":false,"given":"Xin Ying","family":"Lee","sequence":"additional","affiliation":[{"name":"Lundbeck LLC  Deerfield Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3062-8881","authenticated-orcid":false,"given":"Line Pickering","family":"Boserup","sequence":"additional","affiliation":[{"name":"H. Lundbeck A\/S  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3767-7130","authenticated-orcid":false,"given":"Divya","family":"Asher","sequence":"additional","affiliation":[{"name":"Lundbeck LLC  Deerfield Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4714-6010","authenticated-orcid":false,"given":"Seema","family":"Soni\u2010Brahmbhatt","sequence":"additional","affiliation":[{"name":"Lundbeck LLC  Deerfield Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f8rn","family":"Sperling","sequence":"additional","affiliation":[{"name":"H. Lundbeck A\/S  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3260-5904","authenticated-orcid":false,"given":"Peter J.","family":"Goadsby","sequence":"additional","affiliation":[{"name":"NIHR King's Clinical Research Facility and Headache Group King's College London  London UK"},{"name":"King Abdullah University of Science and Technology  Thuwal Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194\u2010017\u20100787\u20101"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2019.06.001"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415\u2010023\u201011880\u20102"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13966"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13613"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102416636055"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410381145"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1515\/sjpain\u20102021\u20100050"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024241269735"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024251320608"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420941839"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474\u20104422(22)00185\u20105"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194\u2010023\u201001688\u2010w"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16131"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15670"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194\u2010022\u201001521\u2010w"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120\u2010020\u201000196\u20102"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14259"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415\u2010023\u201012103\u20104"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024241291578"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14153"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194\u2010022\u201001431\u2010x"},{"key":"e_1_2_12_25_1","unstructured":"National Institute for Health and Care Excellence (NICE) \u201cTechnology Appraisal Guidance: Eptinezumab for Preventing Migraine [TA871] \u201d(2023) https:\/\/www.nice.org.uk\/guidance\/TA871."},{"key":"#cr-split#-e_1_2_12_26_1.1","unstructured":"Pharmaceutical Benefits Advisory Committee (PBAC) \"Public Summary Document (PSD): July 2022 PBAC Meeting-Eptinezumab: Solution Concentrate for I.V Infusion 100 mg in 1\u2009mL"},{"key":"#cr-split#-e_1_2_12_26_1.2","unstructured":"Vyepti \"(2022) https:\/\/www.pbs.gov.au\/info\/industry\/listing\/elements\/pbac\u2010meetings\/psd\/2022\u201007\/eptinezumab\u2010solution\u2010concentrate\u2010for\u2010i\u2010v\u2010infusion\u2010100\u2010mg\u2010in\u20101\u2010ml\u2010vyepti."},{"key":"e_1_2_12_27_1","unstructured":"European Medicines Agency (EMA) \u201cVyepti: EPAR \u2010 Medicine Overview \u201d(2024) https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vyepti."},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.51731\/cjht.2023.537"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2018.1212"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418779543"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194\u2010021\u201001222\u2010w"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194\u2010025\u201001956\u2010x"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415\u2010022\u201011226\u20104"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194\u2010020\u201001171\u2010w"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40122\u2010023\u201000525\u2010x"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582\u2010021\u201000509\u20105"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14692"}],"container-title":["European Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ene.70460","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ene.70460","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ene.70460","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T08:03:35Z","timestamp":1771401815000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ene.70460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1111\/ene.70460"],"URL":"https:\/\/doi.org\/10.1111\/ene.70460","archive":["Portico"],"relation":{},"ISSN":["1351-5101","1468-1331"],"issn-type":[{"value":"1351-5101","type":"print"},{"value":"1468-1331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"2025-07-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70460"}}